Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while leveraging the success of Dupixent and advancing a promising pipeline.

DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory approval. ... Read More The post Phase III Trials: It’s crunch time for these ASX health stocks appeared first on Stockhead.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial Health rating, has positioned itself as an innovative player in the development of antibody-based therapies for cancer treatment.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly in oncology and other key therapeutic areas.

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $133 million, recently reported that Ilan Ganot, a director at the company, engaged in stock transactions that included the sale of common stock valued at approximately $447.

Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On Monday, Nina Kjellson resigned from her position on the Board and the Compensation Committee,

CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Adele Gulfo to its Board of Directors.

Jefferies analyst Akash Tewari adjusted the price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL), bringing it down to $2.50 from the previous figure of $6.00, while reiterating a Hold rating on the company's stock.

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where BridgeBio Pharma, Inc.

Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, according to a statement.